Rapid and convenient assays toassess potential inhibitory activity on in vitro hepatitis a replication

Antiviral Research

Volumn 98, Issue 2, 2013, Pages 325-331

  Debing, Yannick ^a   Kaplan, Gerardo G ^b   Neyts, Johan ^a   Jochmans, Dirk ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Amantadine; Antiviral assay; Enterovirus inhibitor.; Hepatitis A virus; Interferon

Indexed keywords

ALPHA2B INTERFERON; AMANTADINE; ENVIROXIME; PHOSPHATIDYLINOSITOL KINASE; PLECONARIL; RECOMBINANT ALPHA2B INTERFERON; RUPINTRIVIR; ANTIVIRUS AGENT; ALPHA INTERFERON; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG DETERMINATION; GENOTYPE; HEPATITIS A; HEPATITIS A VIRUS; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE; BIOASSAY; CELL LINE; DRUG EFFECT; EVALUATION; GENETICS; HUMAN; METHODOLOGY; PHYSIOLOGY; VIROLOGY; CELL CULTURE; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD; VIRUS STRAIN;

ENTEROVIRUS; HEPATITIS A VIRUS; PHOS;

ANTIVIRAL AGENTS; BIOLOGICAL ASSAY; CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; HEPATITIS A; HEPATITIS A VIRUS; HUMANS; VIRUS REPLICATION;

EID: 84876180078     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.03.016     Document Type: Article

References (37)

1. Bergmann, E.M., Mosimann, S.C., Chernaia, M.M., Malcolm, B.A., James, M.N., 1997. The refined crystal structure ofthe 3Cgene product from hepatitis Avirus: specific proteinase activity and RNA recognition.J.Virol.71, 2436-2448.
2. Binn, L.N., Lemon, S.M., Marchwicki, R.H., Redfield, R.R., Gates, N.L., Bancroft, W.H., 1984. Primary isolation and serial passage ofhepatitis Avirus strains inprimate cell cultures. J.Clin.Microbiol.20, 28-33.
3. Bishop, N.E., 1998.Examination ofpotential inhibitors ofhepatitis Avirus uncoating. Intervirology 41, 261-271.
4. Biziagos, E., Crance, J.M., Passagot, J., Deloince, R., 1990.Inhibitory effect ofatropine, protamine, and their combination onhepatitis Avirus replication inPLC/PRF/5 cells. Antimicrob.Agents Chemother.34, 1112-1117.
5. Bordi, L., Rozera, G., Scognamiglio, P., Minosse, C., Loffredo, M., Anitori, A., Narciso, P., Ippolito, G., Girardi, E., Capobianchi, M.R., GEAS group, 2012.Monophyletic outbreak of hepatitis Ainvolving HIV-infected men who have sex with men, Rome, Italy 2008-2009.J.Clin.Virol.54, 26-29.
6. Costa-Mattioli, M., DiNapoli, A., Ferré, V., Billaudel, S., Perez-bercoff, R., Cristina, J., 2003. Genetic variability ofhepatitis Avirus.J.Gen.Virol.84, 3191-3201.
7. Crance, J.-M., Biziagos, E., Passagot, J., van Cuyck-Gandré, H., Deloince, R., 1990. Inhibition of hepatitis Avirus replication in vitro by antiviral compounds.J. Med. Virol.31, 155-160.
8. Crance, J.-M., Lévêque, F., Chousterman, S., Jouan, A., Trépo, C., Deloince, R., 1995. Antiviral activity ofrecombinant interferon- a on hepatitis Avirus replication in human liver cells. Antiviral Res.28, 69-80.
9. Diana, G.D., Rudewicz, P., Pevear, D.C., Nitz, T.J., Aldous, S.C., Aldous, D.J., Robinson, D.T., Draper, T., Dutko, F.J., Aldi, C., et al., 1995.Picornavirus inhibitors: trifluoromethyl substitution provides aglobal protective effect against hepatic metabolism. J.Med.Chem.14, 1355-1371.
10. Donnan, E.J., Fielding, J.E., Gregory, J.E., Lalor, K., Rowe, S., Goldsmith, P., Antoniou, M., Fullerton, K.E., Knope, K., Copland, J.G., Bowden, D.S., Tracy, S.L., Hogg, G.G., Tan, A., Adamopoulos, J., Gaston, J., Vally, H., 2012.Amultistate outbreak of hepatitis A associated with semidried tomatoes inAustralia, 2009.Clin.Infect. Dis., 775-781.
11. Jeong, S.-H., Lee, H.-S., 2010.Hepatitis A:clinical manifestations and management. Intervirology 53, 15-19.
12. Jochmans, D., Leyssen, P., Neyts, J., 2012.Anovel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE.J. Virol. Methods 183, 176-179.
13. Kanda, T., Imazeki, F., Nakamoto, S., Okitsu, K., Fujiwara, K., Yokosuka, O., 2010. Internal ribosome entry-site activities of clinical isolate-derived hepatitis A virus and inhibitory effects of amantadine.Hepatol.Res.40, 415-423.
14. Kanda, T., Yokosuka, O., Imazeki, F., Fujiwara, K., Nagao, K., Saisho, H., 2005.Amantadine inhibits hepatitis Avirus internal ribosomal entry site-mediated translation in human hepatoma cells.Biochem.Biophys.Res.Commun.331, 621-629.
15. Keeffe, E., 2000.Hepatitis Ainpatients with chronic liver disease -severity of illness and prevention with vaccination. J.Viral.Hepat.7(Suppl.1), 15-17.
16. Konduru, K., Kaplan, G.G., 2006.Stable growth ofwild-type hepatitis Avirus incell culture. J.Virol.80, 1352-1360.
17. Lemon, S.M., Murphy, P.C., Shields, P.A., Ping, L.-H., Feinstone, S.M., Cromeans, T., Jansen, R.W., 1991.Antigenic and genetic variation incytopathic hepatitis A virus variants arising during persistent infection:evidence for genetic recombination. J.Virol.65, 2056-2065.
18. Martin, A., Lemon, S.M., 2006.Hepatitis Avirus:from discovery tovaccines. Hepatology 43, S164-S172.
19. Nainan, O.V., Xia, G., Vaughan, G., Margolis, H.S., 2006.Diagnosis ofhepatitis Avirus infection: amolecular approach.Clin.Microbiol.Rev.19, 63-79.
20. Paget, C.J., Chamberlin, J.W., Wikel, J.H., 1978.Carbonyl-substituted 1- sulfonylbenzimidazoles. USPatent #4118742.
21. Pérez-Sautu, U., Costafreda, M.I., Caylà, J., Tortajada, C., Lite, J., Bosch, A., Pintó, R.M., 2011. Hepatitis Avirus vaccine escape variants and potential new serotype emergence. Emerg.Infect.Dis.17, 734-737.
22. Pevear, D.C., Tull, T.M., Seipel, M.E., Groarke, J.M., 1999.Activity ofpleconaril against enteroviruses. Antimicrob.Agents Chemother.43, 2109-2115.
23. Reed, L.J., Muench, H., 1938.Asimple method for estimating fiftyper cent endpoints. Am.J.Epidemiol.27, 193-197.
24. Shouval, D., 2012.Hepatitis:new doubts about preventing HAV superinfection in chronic HCV. Nat.Rev.Gastroenterol.Hepatol.29, 367-368.
25. Silberstein, E., Xing, L., van deBeek, W., Lu, J., Cheng, H., Kaplan, G.G., 2003.Alteration of hepatitis Avirus (HAV)particles byasoluble form ofHAV cellular receptor 1containing the immunoglobin- and mucin-like regions.J.Virol.77, 8765-8774.
26. Superti, F., Seganti, L., Orsi, N., Divizia, M., Gabrieli, R., Panà, A., 1987.The effect of lipophilic amines on the growth ofhepatitis Avirus inFrp/3 cells.Arch.Virol. 96, 289-296.
27. Tan, J., George, S., Kusov, Y., Perbandt, M., Anemüller, S., Mesters, J.R., Norder, H., Coutard, B., Lacroix, C., Leyssen, P., Neyts, J., Hilgenfeld, R., 2013.3Cprotease of enterovirus 68: structure-based design ofMichael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses.J.Virol.87, 4339-4351.
28. Thibaut, H.J., DePalma, A.M., Neyts, J., 2012.Combating enterovirus replication: state-of-the-art on antiviral research.Biochem.Pharmacol.83, 185-192.
29. van Cuyck-Gandré, H., Job, A., Burckhart, M.F., Girond, S., Crance, J.M., 1995.Use of digoxigenin-labeled RNA probe totest hepatitis Avirus antiviral drugs.Pathol. Biol. (Paris)43, 411-415.
30. van der Schaar, H.M., van der Linden, L., Lanke, K.H., Strating, J.R., Pürstinger, G., de Vries, E., Neyts, J., van Kuppeveld, F.J., 2012.Coxsackievirus mutants that can bypass host factor PI4KIII b and the need for high levels ofPI4P lipids for replication. Cell Res.22, 1576-1592.
31. Vento, S., Garofano, T., Renzini, C., Cainelli, F., Casali, F., Ghironzi, G., Ferraro, T., Concia, E., 1998.Fulminant hepatitis associated with hepatitis Avirus superinfection in patients with chronic hepatitis C.N.Engl.J.Med.29, 286-290.
32. Wasley, A., Fiore, A., Bell, B.P., 2006.Hepatitis Ainthe era ofvaccination.Epidemiol. Rev. 28, 101-111.
33. Widell, A., Hansson, B.G., Oberg, B., Nordenfelt, E., 1986.Influenceoftwenty potentially antiviral substances on in vitro multiplication of hepatitis Avirus. Antiviral Res. 6, 103-112.
34. World Health Organization, 2011.The Immunological Basis for Immunization Series - Module 18:Hepatitis A.WHO Press, Geneva, Switzerland.
35. Yang, Y., Liang, Y., Qu, L., Chen, Z., Yi, M., Li, K., Lemon, S.M., 2007.Disruption of innate immunity due to mitochondrial targeting ofapicornaviral protease precursor. Proc.Natl.Acad.Sci.USA 104, 7253-7258.
36. Yoshiba, M., Inoue, K., Sekiyama, K., 1994.Interferon for hepatitis A.Lancet 343, 288-289.
37. Zhang, J.-H., Chung, T.D.Y., Oldenburg, K.R., 1999.Asimple statistic parameter for use in evaluation and validation ofhigh throughput screening assays.J.Biomol. Screen. 4, 67-73.